Immuneering (IMRX) CEO Benjamin Zeskind Buys 2,400 Shares

What Happened
Benjamin J. Zeskind, President, CEO and Director of Immuneering Corp (IMRX), made an open-market purchase of 2,400 shares on June 23, 2026. The weighted average purchase price reported was $4.56 per share, for a total cash outlay of approximately $10,948. The filing lists the transaction code P (purchase) and the shares were acquired for the benefit of the Benjamin J. Zeskind 2020 Family Trust.

Key Details

• Transaction date: 2026-06-23 (Period of Report); Form 4 filed 2026-06-24 (timely filing).
• Price: weighted average $4.56/share; executed in multiple trades at prices ranging $4.55–$4.59 (footnote F1).
• Shares purchased: 2,400; total value ≈ $10,948.
• Shares owned after transaction: not specified in the filing.
• Beneficial ownership/holding vehicle: held by the Benjamin J. Zeskind 2020 Family Trust; Lisa Schwartz (spouse) is sole trustee (footnote F2).
• Transaction code: P = Purchase. No 10b5-1 plan, tax withholding, or option exercise noted.

Context
This was a direct insider purchase (not an award or option exercise) and is commonly viewed by investors as a more informative signal than routine sales, though it does not guarantee future performance. The filing is timely and discloses the trade was executed across multiple trades — the registrant offers to provide per-trade details to the SEC upon request.